Richter BioLogics GmbH & Co KG’s a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment.
The European pharmacutical sector is still reeling from the pandemic, the energy crisis and various geopolitical conflicts – but this has not stopped progress.
In one new move, Richter BioLogics GmbH & Co KG, a subsidiary of the Gedeon Richter Plc, has inaugurated a state-of-the-art cGMP facility in Bovenau, Schleswig-Holstein, Germany. The opening ceremony saw various dignitaries, including Erik Bogsch, Lifetime Honorary Chairman, members of the Supervisory Board, and top executives from Richter BioLogics, mingling with local political leaders such as Daniel Günther, Minister-President of Schleswig-Holstein and Bovenau’s mayor, Daniel Ambrock.
Innovative installation that stands out
This modern installation positions itself as a powerhouse for research and development, with capabilities to produce protein and plasmid DNA-based products. It champions advanced technologies enabling both clinical and large-scale commercial drug production. Such advancements signify not only substantial economic growth for the town of Bovenau but also noteworthy progress in the realm of pharmaceutical manufacturing globally.
The site, originally established back in 2000, has grown immensely over the years, employing over 125 specialists and boasting a considerable litre fermenter volume. Adhering closely to Good Manufacturing Practice standards, the facility often focuses on microbial production and the supply for both clinical and commercial stages.
With the addition of new 300L and 1500L production lines, the facility now enjoys enhanced flexibility, capable of manufacturing numerous products in up to 120 batches annually. The total manufacturing space spreads across approximately 10,000 sq metres, integrating extensive warehousing, dedicated lab areas for experimental testing and technical spaces designed to optimise both product handling and workforce operations.
Looking ahead to the end of 2024, projections suggest that this expansion will more than double the skilled workforce, reaching a landmark figure of over 400 local employees.
“Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics’ growth strategy. With one of Richter’s largest investments in the last decade, we have positioned ourselves as a key player in meeting global market demand and supplying the global pharmaceutical industry with the highest quality biopharmaceutical products. We also increase our flexibility, one of our biggest and most valued strengths,” said Dr. Kai Pohlmeyer, Managing Director at Richter BioLogics.
“This investment demonstrates a strong commitment to the future of Richter BioLogics, to innovation and to GMP manufacturing of biopharmaceuticals made in Germany and to Richter’s commitment to biological products. This new facility together with our existing facilities in Hungary provide for a fully integrated R&D and manufacturing biologics capability, allowing for further access to such medicines to patients worldwide,” said Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter.
The strategic expansion of Richter BioLogics
Gedeon Richter Plc, the parent company, is a trailblazer in the speciality pharmaceutical sector, driven by ceaseless innovation since its inception in 1901. With a global footprint spanning over 50 countries and a robust workforce of 11,603, this Hungarian powerhouse undertakes a broad spectrum of operations encompassing development, production and marketing of pharmaceutical solutions.
At its core, Gedeon Richter operates with a vertically integrated model, maintaining oversight across all stages of pharmaceutical production, from research through to sales. This comprehensive control ensures high standards are met consistently, thereby enhancing health outcomes and quality of life for their global consumer base. In alignment with its strategic vision since 2018, the company aims to reinforce its prominence among European pharmaceutical leaders. This latest extension via Richter BioLogics embodies that very ambition, steering further expansion throughout Europe and fostering advancements in healthcare technology.
The new Bovenau facility is just the beginning. It heralds a new era of growth and innovation for Richter BioLogics, bringing forth a significant technological leap that promises to reshape the industry dynamics and improve healthcare delivery with more precision and efficiency.
